Fannin launches Radiomer Therapeutics with novel targeting vector/ligand platform for radiopharmaceuticals
Fannin Partners announces today that Radiomer Therapeutics has been launched with undisclosed pre-seed funding to continue aggressive development of its radiopharmaceutical/ radioligand therapy platform and programs. Radiomer joins a Fannin portfolio that has amassed more than $240 million of aggregate investor, partner and grant investment. Radiomer leverages Fannin's proprietary RaptamerTM platform as targeting vectors/ligands for theranostic application.
To read more:
